High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN

Interesting that they don't seem to be following the FDA guidelines on high dose statins. So ask your doctor how to reverse atherosclerosis naturally. I've written about a number of ways to do that. If your doctor doesn't know, you need to fire him/her and call the hospital president for continuing to employ doctors that aren't up-to-date on current practices. It's time to go to the mat on this, we have to remove all incompetent doctors.

FDA announces new safety recommendations for high-dose simvastatin 

http://www.ncbi.nlm.nih.gov/pubmed/25190674

Stegman B¹, Puri R², Cho L¹, Shao M³, Ballantyne CM⁴, Barter PJ⁵, Chapman MJ⁶, Erbel R⁷, Libby P⁸, Raichlen JS⁹, Uno K¹, Kataoka Y¹⁰, Nissen SE², Nicholls SJ¹¹.

Author information

Abstract

OBJECTIVE:

Although statins can induce coronary atheroma regression, this benefit has yet to be demonstrated in diabetic individuals. We tested the hypothesis that high-intensity statin therapy may promote coronary atheroma regression in patients with diabetes.

RESEARCH DESIGN AND METHODS:

The Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) used serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months. This analysis compared changes in biochemistry and coronary percent atheroma volume (PAV) in patients with (n = 159) and without (n = 880) diabetes.

RESULTS:

At baseline, patients with diabetes had lower LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C) levels but higher triglyceride and CRP levels compared with patients without diabetes. At follow-up, diabetic patients had lower levels of LDL-C (61.0 ± 20.5 vs. 66.4 ± 22.9 mg/dL, P = 0.01) and HDL-C (46.3 ± 10.6 vs. 49.9 ± 12.0 mg/dL, P < 0.001) but higher levels of triglycerides (127.6 [98.8, 163.0] vs. 113.0 mg/dL [87.6, 151.9], P = 0.001) and CRP (1.4 [0.7, 3.3] vs. 1.0 [0.5, 2.1] mg/L, P = 0.001). Both patients with and without diabetes demonstrated regression of coronary atheroma as measured by change in PAV (-0.83 ± 0.13 vs. -1.15 ± 0.13%, P = 0.08). PAV regression was less in diabetic compared with nondiabetic patients when on-treatment LDL-C levels were >70 mg/dL (-0.31 ± 0.23 vs. -1.01 ± 0.21%, P = 0.03) but similar when LDL-C levels were ≤70 mg/dL (-1.09 ± 0.16 vs. -1.24 ± 0.16%, P = 0.50).

CONCLUSIONS:

High-intensity statin therapy alters the progressive nature of diabetic coronary atherosclerosis, yielding regression of disease in diabetic and nondiabetic patients.